Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Generic Name: Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Indication: 用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；

2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；

3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；

4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；

5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Clinical Trials

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Biological: PROSTVAC-V
Biological: PROSTVAC-F
Biological: Placebo
Other: GM-CSF Placebo
Drug: GM-CSF

First Posted Date: 2011-03-24

Last Posted Date: 2019-09-04

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 1297

Registration Number: NCT01322490

Locations: 🇺🇸
Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States
🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸
Alta Bates Summit Medical Center, Berkeley, California, United States

and more 216 locations

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions: Biological: Galinpepimut-S
Biological: GM-CSF
Other: Montanide

First Posted Date: 2010-12-24

Last Posted Date: 2024-11-19

Lead Sponsor: Sellas Life Sciences Group

Target Recruit Count: 22

Registration Number: NCT01266083

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

Phase 2

Terminated

Conditions: Myeloma

Interventions: Biological: KLH Vaccine
Biological: KLH-id Vaccine
Drug: GM-CSF
Procedure: Donor Lymphocyte Infusion (DLI)
Procedure: Apheresis

First Posted Date: 2010-08-03

Last Posted Date: 2018-06-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01174082

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Novel Interventions in HIV-1 Infection

Phase 1

Terminated

Conditions: HIV-1 Infection

Interventions: Biological: GTU-MultiHIV B clade vaccine1mg
Drug: Interleukin-2
Drug: GM-CSF
Drug: Growth Hormone

First Posted Date: 2010-05-26

Last Posted Date: 2013-09-04

Lead Sponsor: Imperial College London

Target Recruit Count: 12

Registration Number: NCT01130376

Locations: 🇬🇧
St. Stephen's AIDS Trust, London, United Kingdom

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma
Hodgkin's Disease
Multiple Myeloma
Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)
Leukemia

Interventions: Drug: GM-CSF
Drug: IL-2

First Posted Date: 2009-08-06

Last Posted Date: 2018-04-25

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 13

Registration Number: NCT00952237

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

Phase 2

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2009-07-29

Last Posted Date: 2016-07-15

Lead Sponsor: Hoag Memorial Hospital Presbyterian

Target Recruit Count: 56

Registration Number: NCT00948480

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: GM-CSF (Sargramostim)
Drug: Rituximab

First Posted Date: 2009-07-16

Last Posted Date: 2018-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 130

Registration Number: NCT00940342

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: GM-CSF

First Posted Date: 2009-04-13

Last Posted Date: 2009-04-13

Lead Sponsor: Acute Leukemia French Association

Target Recruit Count: 473

Registration Number: NCT00880243

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: GM-CSF
Biological: Dendritic Cell/Tumor Fusion Vaccine
Drug: imiquimod

First Posted Date: 2008-11-27

Last Posted Date: 2024-06-11

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 23

Registration Number: NCT00799110

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: GM-CSF

First Posted Date: 2008-05-15

Last Posted Date: 2017-08-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 30

Registration Number: NCT00678054

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy